Compound ID | 1301
Class: Antimicrobial peptide
Spectrum of activity: | Gram-negative |
Details of activity: | Bactericidal activity against colistin- susceptible and -resistant isolates of P. aeruginosa, and against colistin-susceptible K. pneumoniae. Combined therapy on XDR A. baumannii, K. pneumoniae and P. aeruginosa strains, gave synergy for M33/meropenem on two of the six strain, for M33/rifampin on three out of six strains, for M33/aztreonam on three out of six strains and for M33/tobramycin on one out of six strains. |
Institute where first reported: | University of Siena; University of Florence; Erasmus Mc; Medical Microbiology & Infectious Diseases; Erasmus University Medical Centre (Erasmus Mc); Medical Microbiology & Infectious Diseases; University of Florence; Forence Careggi University Hospital; Don Carlo Gnocchi Foundation; Clinical Microbiology and Virology Unit, Florence Careggi University Hospital, Florence; University of Siena; Medical Biotechnology; University of Siena; Department of Medical Biotechnology |
Year first mentioned: | 2017 |
Highest developmental phase: | Preclinical |
Development status: | Active |